Bivalent norovirus vaccine - National Vaccine and Serum Institute
Alternative Names: Norovirus Bivalent (GI.1 / GII.4) Vaccine - National Vaccine and Serum InstituteLatest Information Update: 28 Dec 2022
At a glance
- Originator National Vaccine & Serum Institute
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Norovirus infections
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Norovirus-infections(In adolescents, In children, In infants, Prevention, In adults) in China (IM)
- 13 Dec 2020 National Vaccine and Serum Institute completes a phase I trial in Norovirus Infections (Prevention, In adolescents, In children, In adults, In infants) in China (IM) (NCT04188691)